Sanofi India primarily deals with the Manufacture and sale of pharmaceutical products.
Financial Results:
The company reported a decline of 2.32% YoY in revenue from operations which stood at INR 671.9 crore in the third quarter of FY23, as compared to INR 687.90 crore in the year-ago quarter. In the period ended December 2022, the company reported net expenses of INR 515.4 crore. This is against INR 572 crore that the company posted in the previous year’s quarter.
In the third quarter of FY23, Sanofi India’s profit increased by 44.80% YoY standing at INR 130.9 crore as against INR 90.4 crore. The earnings per share increased from INR 39.25 (recorded in Q3FY22) to INR 56.84 in Q3FY23.